Compare AYTU & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AYTU | VTGN |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 21.8M |
| IPO Year | 2015 | 2014 |
| Metric | AYTU | VTGN |
|---|---|---|
| Price | $2.63 | $0.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $9.33 | $0.90 |
| AVG Volume (30 Days) | 45.8K | ★ 471.6K |
| Earning Date | 05-13-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,632,080.00 | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | $43.75 | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $0.95 | $0.43 |
| 52 Week High | $3.07 | $5.14 |
| Indicator | AYTU | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 40.05 |
| Support Level | $2.14 | $0.50 |
| Resistance Level | $2.66 | $0.60 |
| Average True Range (ATR) | 0.10 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 60.87 | 6.32 |
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.